

Roles of Cytoplasmic Phospholipase in Expression of the Antimicrobial Activity of Host Macrophages against *Mycobacterium tuberculosis* Infection

Chiaki SANO, Ko YASUMOTO, Yutaka TATANO, Toshiaki SHIMIZU, Seiko YAMABE and Haruaki TOMIOKA
Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan

(Received August 26, 2010; Accepted; October 19, 2010)

We studied roles of phospholipase A₂ (PLA₂) isozymes, including type IIA secretory PLA₂ (sPLA₂-IIA), type IV cytosolic, Ca²⁺-dependent PLA₂ (cPLA₂), type V secretory PLA₂ (sPLA₂-V), and type VI cytosolic, Ca²⁺-independent PLA₂ (iPLA₂), in macrophage (Mφ) antimicrobial activity against *Mycobacterium tuberculosis* (Mtb) H37Ra (avirulent) strain and Mφ mRNA expression of these PLA₂ isotypes in response to infection with the microorganisms. First, a cPLA₂ inhibitor arachidonyl trifluoromethylketone mildly reduced Mφ anti-Mtb activity, while the other PLA₂ inhibitors did not significantly block the Mφ antimycobacterial function, if any. Second, Mφ expression of cPLA₂ and sPLA₂-V mRNAs was up-regulated during 6 to 12 h after infection with Mtb H37Ra strain. These findings suggest that cPLA₂ plays a role in cellular mechanisms participating in the expression of Mφ anti-Mtb activity.

Key words: *Mycobacterium tuberculosis*, macrophages, phospholipase A₂, antimicrobial activity

INTRODUCTION

Macrophages (Mφs) play a central role as antimicrobial effector cells in the expression of host resistance to *Mycobacterium tuberculosis* (Mtb). Reactive nitrogen intermediates (RNIs) have been demonstrated to play an important role in the activity of Mφs against Mtb (1, 2, 3). Studies employing inducible nitric oxide synthase (iNOS) gene-disrupted mice indicated that RNIs were required for the activity of Mφs against Mtb (4, 5). With respect to the role

of reactive oxygen intermediates (ROIs), it has been reported that ROIs are insufficient to inhibit and/or kill Mtb (3, 4, 6, 7), although some investigators including us indicated possible roles of ROIs, such as H₂O₂-mediated halogenation system, in intramacrophage killing of Mtb (8, 9).

We previously found that there was no relationship between the degree of susceptibility of a given *Mycobacterium avium* complex (MAC) strain to RNIs and ROIs and its virulence in mice (10). Thus, RNIs and ROIs each alone are not decisive as effector components of the host defence mechanism against MAC, and alternative antimicrobial effectors may be involved in the antimycobacterial activity of Mφs. We also found that unsaturated long-chain free fatty acids, such as oleic acid, linoleic acid, linolenic acid, and arachidonic acid, exhibited strong antimycobacterial activity (11). In addition, intramacrophage growth of Mtb was accelerated by an inhibitor of type IV cytosolic phospholipase A₂ (cPLA₂), arachidonyl trifluoromethylketone (a-TFMK) (12). These findings support the concept that free fatty acids, especially arachidonic acid, may play important roles in Mφ antimicrobial function against mycobacterial pathogens including Mtb and MAC. In this study, to determine the roles of other PLA₂ isozymes than cPLA₂, such as type IIA secretory PLA₂ (sPLA₂-IIA), type V secretory PLA₂ (sPLA₂-V), and type VI cytosolic, Ca²⁺-independent PLA₂ (iPLA₂) (13) in Mφ anti-Mtb antimicrobial function, we examined the effects of various PLA₂ inhibitors on Mφ antimicrobial activity against Mtb. In addition, we studied profiles of intracellular expression of these PLA₂ isotypes in Mtb-infected Mφs.

Correspondence: Haruaki Tomioka, Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
Tel: +81-853-20-2146
Fax: +81-853-20-2145
E-mail: tomioka@med.shimane-u.ac.jp

MATERIALS AND METHODS

Microorganisms

Attenuated Mtb H37Ra strain (ATCC 25177) was

used. The organisms were cultured in Middlebrook 7H9 broth and bacterial suspension prepared with phosphate-buffered saline (PBS) containing 1% bovine serum albumin was used as an inoculum.

Special agents

Special agents used in this study were as follows: manoalide (Wako Pure Chemical Industries, Ltd., Osaka Japan), cyclic (2-NaphthylAla-Leu-Ser-2-NaphthylAla-Arg)trifluoroacetate salt, GIIA-Inh (SPI525145) (Calbiochem, San Diego, CA), arachidonyl trifluoromethylketone (a-TFMK) (Sigma Chemicals Co., St. Louis, MO), N-{(2S,4R)-4-(Biphenyl-2-ylmethylisobutyl-amino)-1-[2-(2,4-difluorobenzoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl] acrylamide (CPI525143) (Calbiochem), 12-episcalaradiol (EPR) (Wako), and bromoenol lactone (BEL) (Sigma). These agents were initially dissolved in dimethyl-sulfoxide (DMSO) at 50 mM.

Fig. 1 shows chemical structures of various PLAs inhibitors. IC₅₀ values against PLA₂ are as fol-

lows. Manoalide: 4.7 μM against human recombinant sPLA₂, SPI525145: 12.8 μM against human sPLA₂-II A, a-TFMK: 0.3 μM against U937 cPLA₂, CPI525143: 1.8 nM against cPLA₂α, EPR: 5.4 μM against human recombinant sPLA₂, BEL: 0.03 μM against myocardial iPLA₂.

Macrophage monolayer culture

Peritoneal cells collected from 8-12-week-old BALB/c mouse given an i.p. injection 1mg zymosan A (Sigma) 4 days before. Mφ monolayer cultures were prepared either by seeding 1.5 x 10⁵ of zymosan A-induced peritoneal exudate cells in RPMI 1640 medium containing 5% fetal bovine serum (FBS) and 25 mM HEPES (designated RPMI medium) on a 96-well flat-bottomed microculture well. In some experiments, mouse macrophage cell lines RAW 264.7 (ATCC TIB-78, derived from BALB/c) were used. 1 x 10⁶ of RAW 264.7 Mφs seeded on a 60-mm culture dish followed by subsequent 3-day cultivation in 5 ml of 5% FBS-RPMI medium containing 500 units/ml IFN-γ.




Fig. 1. Chemical structures of various PLA₂ inhibitors in this study.

MTT cytotoxicity assay

Monolayer cultures of mouse peritoneal M ϕ s were cultured in 0.2 ml of 5% FBS-RPMI medium with or without test agents for 24 h. After medium change with test drug-free fresh 5% FBS-RPMI medium containing 5 mg/ml of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (Dojindo, Tokyo, Japan), the M ϕ s were incubated for 3 h, cell-associated MTT was extracted with DMSO, and measured for the optical density at 550nm.

Macrophage antimicrobial activity against Mtb

For measurement of M ϕ antimicrobial activity, the monolayer cultures of mouse peritoneal M ϕ s were incubated in 0.1 ml of RPMI medium containing 7.5×10^4 CFU/ml of Mtb H37Ra in a CO₂ incubator for 2 h. Infected M ϕ s were then washed with Hanks' balanced salt solution containing 2% FBS to remove extracellular organisms, and thereafter cultivated in 0.2 ml of RPMI medium with or without the addition of test agents. After 3- and 5-day cultivation, the M ϕ s were lysed with 0.07% SDS and the number of CFU in resulting cell lysate was counted on 7H11 agar plates.

Measurement of expression of PLA₂ and iNOS mRNAs

RT-PCR analysis of PLA₂ and iNOS mRNAs in Mtb-phagocytizing M ϕ s was performed as follows. Monolayer cultures of RAW264.7 M ϕ s were incubated in 5 ml of RPMI medium containing 500 units/ml IFN- γ and 1×10^6 CFU/ml of UV-killed Mtb for up to 12 h. At intervals, total RNA was isolated from cultured M ϕ s using the ISOGEN kit (Nippon Gene Co., Toyama, Japan). After DNase-I treatment, the resultant RNA samples were reverse transcribed using random hexamer primers and 200 units Superscript II reverse transcriptase. One μ l of aliquots of resultant cDNA was amplified by PCR in the standard reaction mixture containing 1 x PCR buffer, 0.2 mM of each dNTP, 1 unit of Taq polymerase, and 20 pmoles of sense and antisense primers for test PLA₂ (synthesized by Greiner Labortechnik Co., Tokyo, Japan) as follows (sense/antisense): sPLA₂-IIA (CGGCT-

TAAGACAGGAAAGAGAG/TGCCAAAACATGTTGGGGTAGAA), cPLA₂ (CTTACACCACAGAAAGT-TAAAAGAT/AAATAGGTCAGGAGCCATAAA), sPLA₂-V (CAGGGGGCTTGCTAGAACTCAA/AAGAGGGTTGTAAGTCCAGAGG), iNOS (CCTGCTCACTCAGCCAAG/AGTCATGGAGCCGCTGCT) β -actin (TGGGAATCCTGCGGCATCCATGAAAC/TAAAACGCAGCTCAGTAACAGTCCG). Reactions were carried out in a DNA thermal cycler for 30 cycles including denaturing at 94°C for 1 min, annealing at 58°C for 2 min, and extension at 72°C for 2 min for each cycle. PCR products were analyzed by electrophoresis on ethidium bromide-stained 2% agarose gels. Intensity of the PLA₂ bands were determined with public software NIH image. iPLA₂ mRNA was not done, since an appropriate primer set could not be provided.

RESULTS AND DISCUSSION

Fig. 2 shows the cytotoxic effects of various PLA₂ inhibitors, including manoalide (sPLA₂-IIA inhibitor), SPI525145 (sPLA₂-IIA inhibitor), a-TFMK (cPLA₂ inhibitor), CPI525143 (cPLA_{2 α inhibitor), 12-episcalaradial (EPR) (sPLA₂-V inhibitor), and}




Fig. 2. Cytotoxic effects of various PLA₂ inhibitors. Cytotoxicity of test agents added at 1 μ M (open bar), 10 μ M (gray bar), and 50 μ M (shaded bar) was measured by the MTT assay.

bromo-enol lactone (BEL) (iPLA₂ inhibitor) on mouse peritoneal macrophages. All the tested PLA₂ inhibitors showed no cytotoxic effect when added at 1 μ M. These drugs except SPI525145 exerted strong cytotoxicity when added at 50 μ M. Manoalide and EPR but not the other inhibitors including a-TFMK, CPI525143, and BEL exhibited partial levels of cytotoxicity at 10 μ M. Based on these findings, we then examined the effects of these PLA₂ inhibitors on M ϕ antimicrobial activity against Mtb H37Ra strain. In this experiment, zymosan A-activated mouse peritoneal M ϕ s were used, because it has been indicated that their cytoplasmic PLA₂ activity is significantly increased in response to mycobacterial infection (14). Notably, a-TFMK suppressed the bactericidal activity of M ϕ s against Mtb organisms residing in M ϕ s but the effect was non-significant (Fig. 3). The other tested agents failed to exert such a blocking activity. Therefore, it appears that type IV cPLA₂ plays some roles in M ϕ killing activity against Mtb H37Ra strain. Notably, in the present

experiment, the number of intramacrophage Mtb was decreased during the course of 5-day cultivation in a drug-free medium, presumably due to the M ϕ antimycobacterial ability connected with M ϕ apoptosis induced by mycobacterial infection (15, 16). We previously found that a-TFMK exhibited a blocking activity against the anti-Mtb antimicrobial activity of IFN- γ -activated mouse peritoneal M ϕ s (12). In this case, intramacrophage Mtb showed one-log growth during the chase cultivation of infected M ϕ s in a drug-free medium. As recently reported by Garedeew *et al.*, IFN- γ -activated M ϕ s prevent apoptotic cell death by utilizing glycolytic ATP to maintain mitochondrial membrane potential, differing from the case of mildly activated M ϕ s, such as zymosan A-stimulated peritoneal M ϕ s (17). This may be the reason that in IFN- γ -treated M ϕ s, intracellular bacterial growth of infected Mtb was seen without causing M ϕ apoptosis-associated bacterial killing, as in the case of zymosan A-induced M ϕ s indicated in Fig. 3.




Fig. 3. Effects of various PLA₂ inhibitors on M ϕ anti-Mtb antimicrobial activity. Mtb H37Ra-infected M ϕ s were cultured in 5% FBS-RPMI medium in the presence or absence of the PLA₂ inhibitors at indicated concentrations. After 3-day (A) or 5-day (B) cultivation, the number of residual CFU of intramacrophage Mtb was counted on 7H11 agar plates. For solute control, infected M ϕ s were cultured RPMI medium containing 0.01% DMSO. Each bar indicates the mean + SEM (n=3).

In separate experiments where Mφs were infected with Mtb at a higher dose (1.5×10^5 CFU/well), 1 μM manoalide, 0.05 μM CPI525143, 6 μM EPR, and 1 μM BEL also attenuated the Mφ bacterial killing activity (data not shown). However, the reproducibility of this finding was somewhat low. In this context, it should be noted that the specificity of these PLA₂ inhibitors are not perfectly strict. For instance, it has been demonstrated that manoalide at 10 μM concentration actually inhibited sPLA₂-V activity (18). Moreover, it has been reported that manoalide weakly inhibits cPLA₂ activity (19). Therefore, although the above PLA₂ inhibitors, especially a-TFMK, are capable of blocking Mφ antimicrobial activity against Mtb, it is concluded that their effects are mild, indicating the participation of PLA₂, particularly type IV cPLA₂, in Mφ antimicrobial activity against intramacrophage mycobacteria is partial but not crucial as we previously proposed (8, 10, 12).

Next, we examined profiles of the expression of sPLA₂-IIA, cPLA₂, sPLA₂-V, and iNOS mRNAs in Mtb-phagocytizing Mφs during chase cultivation after bacterial phagocytosis. The following results were obtained. First, even in the control Mφs before bacterial contact, cPLA₂, sPLA₂-V, and iNOS mRNAs were constitutively expressed (Fig. 4, lane 1). In this case, cPLA₂ mRNA expression was much weaker than that of sPLA₂-V mRNA. Notably, the expression of sPLA₂-IIA mRNA was not detected in control Mφs. Second, in Mφs stimulated by phagocytosis of Mtb H37Ra strain, cPLA₂ mRNA expression was temporarily reduced for 3 to 6 h after bacterial phagocytosis (Fig. 4, lanes 2, 3). In this case, sPLA₂-V and iNOS mRNA expression were also decreased 3 h after bacterial internalization (Fig. 4, lane 2). At later stages, especially 6 to 12 h after bacterial phagocytosis (only 12 h in the case of cPLA₂), the expression of all these mRNAs increased to some extent compared to those of control Mφs (lanes 3 and 4). Concerning the temporary reduction of the mRNA expression of cPLA₂ and sPLA₂-V seen around 3 to 6 h after phagocytosis of Mtb, the following speculation may be provided. Mφ stimulation in response to triggering of CD14 and Toll-like receptor (TLRs) molecules, such as TLR2-triggering with mycobacterial lipoproteins and




Fig. 4. Profiles of mRNA expression of cPLA₂, sPLA₂-IIA, sPLA₂-V, and iNOS by Mφs after stimulation due to phagocytosis of Mtb organisms. Test Mφs, which phagocytosed UV-killed Mtb H37Ra strain, were subsequently cultivated in RPMI medium for up to 12 h. The values in parentheses are PLA₂ band/β-actin band ratios. The β-actin band intensity indicated as 1.0.

lipoarabinomannan, cause prompt increase in cPLA₂ activity within minutes, thereby resulting in the generation of prostaglandins (especially prostaglandin E₂) (20-22) and causes up-regulation of mRNA expression of cPLA₂ and presumably sPLA₂-V in periods later than several hours after bacterial phagocytosis (20). The mRNA expression of these two PLA₂ enzymes may be temporarily depressed during the first 3 to 6 h due to the down-regulatory effect of prostaglandin E₂, which suppresses Mφ expression of some types of PLA₂, such as sPLA₂-IIA (23). Further studies are necessary to justify this speculation.

Notably, in our RT-PCR system, sPLA₂-IIA mRNA was under the detection level in any stages of 3- to 12-h cultivation after phagocytosis of Mtb H37Ra. The same phenomenon was also observed for Mφs infected with Mtb H37Rv (virulent) strain.

In our previous study using IFN- γ -activated mouse peritoneal M ϕ s with or without stimulation with mycobacterial phagocytosis, significant sPLA₂-IIA mRNA expression was also under detectable levels (12). However, these results do not necessarily indicate that M ϕ s are lacking in the sPLA₂-IIA mRNA expression, since a low level expression of sPLA₂-IIA mRNA (about 1/10 of cPLA₂ mRNA expression) has been reported in certain types of M ϕ s, such as human monocyte-derived M ϕ s (24). In any case, it can be concluded that the test M ϕ s (IFN- γ -treated RAW 267.4 M ϕ s) exhibited very low ability in expressing sPLA₂-IIA mRNA even after Mtb infection. Therefore, it is likely that sPLA₂-IIA plays only a trivial role in the expression of M ϕ antimicrobial activity against Mtb organisms.

It is noted that CPI525143 (cPLA₂ α inhibitor) did not suppress M ϕ anti-Mtb activity, although a-TFMK (cPLA₂ inhibitor) exhibited a blocking activity of the M ϕ anti-Mtb function (Fig. 3). This suggests that cPLA₂ isoform (s) other than the isoform 2 α may dominantly participates in the expression of M ϕ antimycobacterial activity. Indeed, the Western blotting analysis by Duan *et al.* indicated that strong expression of PLA₂ γ isotype but not PLA₂ α isotype in human monocyte-derived M ϕ s was induced during 6-h cultivation after Mtb infection and that this phenomenon was associated with M ϕ apoptosis and concomitant expression of M ϕ antimycobacterial function (25).

The findings in our previous studies imply that arachidonic acid produced by the enzymatic action of cPLA₂ plays an important role as antimycobacterial effectors in the expression of M ϕ antimicrobial activity against mycobacterial pathogens including Mtb and MAC (8, 12, 26). In this context, the recent finding by Vandal *et al.* is noteworthy. Using bone marrow-derived M ϕ s obtained from type IV cPLA₂-deficient mice, they demonstrated that cPLA₂ enzymes are not required by the M ϕ s for control of intracellularly growing Mtb organisms (27). While Vandal *et al.* used Mtb H37Rv (virulent strain) in their study (27), we used Mtb H37Ra (avirulent strain) or a low-virulence MAC in our previous studies that demonstrated significant roles of cPLA₂-dependent mechanisms in expression of M ϕ antimycobacterial activity in vitro (8, 12, 26).

Therefore, it appears that cPLA₂ enzymes may be required for intramacrophage killing/inhibition of low-virulence mycobacterial organisms but not for killing/inhibition of high-virulence Mtb. This concept is supported by the finding by Harwig *et al.* that a mouse-avirulent *Salmonella typhimurium* mutant strain was much more susceptible to the bactericidal action of iPLA₂ than its isogenic virulent parent *S. typhimurium* strain (28). In this context, another possibility remains that other antimicrobial effectors than arachidonic acid play crucial roles in the expression of M ϕ anti-Mtb activity in the case of cPLA₂-deleted M ϕ s reported by Vandal *et al.* (27), because they used cPLA₂-deficient mice of C3H/HeN background with *Nramp1*^{+/+} (*bcg*^r) genotype. Since *Nramp1/Slc11a1* gene encodes a proton-coupled bivalent metal/iron transporter expressed within the late endosomes / lysosomes of M ϕ s (29) and iron is important for Fenton reaction that generates highly bactericidal reactive oxygen intermediates (ROIs) from superoxide anion and hydrogen peroxide, consequently enabling host M ϕ s to effectively killing invading mycobacterial pathogens (30, 31), cPLA₂-deleted M ϕ s, which Vandal *et al.* used, are regarded to exhibit sufficiently effective levels of ROI-mediated antimicrobial functions against Mtb organisms. Overall, it can be concluded that the cPLA₂-mediated antimicrobial mechanism partially participates in M ϕ 's bactericidal and bacteriostatic function against mycobacterial pathogens but such cPLA₂-dependent mechanism does not play a central role in the M ϕ antimycobacterial function. It is of interest to examine the therapeutic effects of regimens involving cPLA₂ modulator in combination with the first-line antituberculous drugs. As we previously proposed, the collaborating action of arachidonic acid generated by enzymatic action of cPLA₂ and other types of antimicrobial effector molecules, such as RNIs and cathepsin D is crucial for the expression of M ϕ antimycobacterial activity.

ACKNOWLEDGMENTS

We thank Ms. Rumi Matsubara, Center for Integrated Research in Science, for her skillful technical assistance.

REFERENCES

- 1) Chan J, Xing Y, Magliozzo RS and Bloom BR (1992) Killing of virulent *Mycobacterium tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. *J Exp Med* 175: 1111-1122.
- 2) MacMicking J, Xie QW and Nathan C (1997) Nitric oxide and macrophage function. *Annu Rev Immunol* 15: 323-350.
- 3) Sato K, Akaki T and Tomioka H (1998) Differential potentiation of anti-mycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages activated by interferon-gamma (IFN- γ) and tumour necrosis factor-alpha (TNF- α). *Clin Exp Immunol* 112: 63-68.
- 4) Adams LB, Dinauer MC, Morgenstern DE and Krahenbuhl JL (1997) Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to *Mycobacterium tuberculosis* using transgenic mice. *Tuber Lung Dis* 78: 237-246.
- 5) MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK and Nathan CF (1997) Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc Natl Acad Sci USA* 94: 5243-5248.
- 6) Manca C, Paul S, Barry CE 3rd, Freedman VH and Kaplan G (1999) *Mycobacterium tuberculosis* catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. *Infect Immun* 67: 74-79.
- 7) Warwick-Davies J, Lowrie DB and Cole PJ (1995) Selective deactivation of human monocyte functions by TGF- β . *J Immunol* 155: 3186-3193.
- 8) Akaki T, Sato K, Shimizu T, Sano C, Kajitani H, Dekio S and Tomioka H (1997) Effector molecules in expression of the antimicrobial activity of macrophages against *Mycobacterium avium* complex: roles of reactive nitrogen intermediates, reactive oxygen intermediates, and free fatty acids. *J Leukoc Biol* 62: 795-804.
- 9) Laochumroonvorapong P, Paul S, Manca C, Freedman VH and Kaplan G (1997) Mycobacterial growth and sensitivity to H₂O₂ killing in human monocytes in vitro. *Infect Immun* 65: 4850-4857.
- 10) Tomioka H, Sato K, Sano C, Akaki T, Shimizu T, Kajitani H and Saito H (1997) Effector molecules of the host defence mechanism against *Mycobacterium avium* complex: the evidence showing that reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids each alone are not decisive in expression of macrophage antimicrobial activity against the parasites. *Clin Exp Immunol* 109: 248-254.
- 11) Saito H and Tomioka H (1988) Susceptibilities of transparent, opaque, and rough colonial variants of *Mycobacterium avium* complex to various fatty acids. *Antimicrob Agents Chemother* 32: 400-402.
- 12) Akaki T, Tomioka H, Shimizu T, Dekio S and Sato K (2000) Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the anti-microbial activity of macrophages against *Mycobacterium tuberculosis*. *Clin Exp Immunol* 121: 302-310.
- 13) Kudo I and Murakami M (2002) Phospholipase A₂ enzymes. *Prostaglandins Other Lipid Mediat* 68-69: 3-58.
- 14) Qiu ZH, de Carvalho MS and Leslie CC (1993) Regulation of phospholipase A₂ activation by phosphorylation in mouse peritoneal macrophages. *J Biol Chem* 268: 24506-24513.
- 15) Fairbairn IP (2004) Macrophage apoptosis in host immunity to mycobacterial infections. *Biochem Soc Trans* 32: 496-498.
- 16) Bocchino M, Galati D, Sanduzzi A, Colizzi V, Brunetti E and Mancino G (2005) Role of mycobacteria-induced monocyte/macrophage apoptosis in the pathogenesis of human tuberculosis. *Int J Tuberc Lung Dis* 9: 375-383.
- 17) Garedew A, Henderson SO and Moncada S (2010) Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. *Cell Death Differ* 2010 Mar 26 (Online).
- 18) Balsinde J, Shinohara H, Lefkowitz LJ, Johnson CA, Balboa MA and Dennis EA (1999) Group V phospholipase A₂-dependent induction of cyclooxygenase-2 in macrophages. *J Biol Chem* 274: 25967-25970.
- 19) Grange E, Rabin O, Bell J and Chang MC

- (1998) Manoalide, a phospholipase A₂ inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. *Neurochem Res* 23: 1251-1257.
- 20) Dieter P, Kolada A, Kamionka S, Schadow A and Kaszkin M (2002) Lipopolysaccharide-induced release of arachidonic acid and prostaglandins in liver macrophages: regulation by Group IV cytosolic phospholipase A₂, but not by Group V and Group IIA secretory phospholipase A₂. *Cell Signal* 14: 199-204.
- 21) Qi HY and Shelhamer JH (2005) Toll-like receptor 4 signaling regulates cytosolic phospholipase A₂ activation and lipid generation in lipopolysaccharide-stimulated macrophages. *J Biol Chem* 280: 38969-38975.
- 22) Noor S, Goldfine H, Tucker DE, Suram S, Lenz LL, Akira S, Uematsu S, Girotti M, Bonventre JV, Breuel K, Williams DL and Leslie CC (2008) Activation of cytosolic phospholipase A₂ α in resident peritoneal macrophages by *Listeria monocytogenes* involves listeriolysin O and TLR2. *J Biol Chem* 283: 4744-4755.
- 23) Vial D, Arbibe L, Havet N, Dumarey C, Vargaftig B and Touqui L (1998) Down-regulation by prostaglandins of type-II phospholipase A₂ expression in guinea-pig alveolar macrophages: a possible involvement of cAMP. *Biochem J* 330: 89-94.
- 24) Lindbom J, Ljungman AG and Tagesson C (2005) Interferon γ -induced gene expression of the novel secretory phospholipase A₂ type IID in human monocyte-derived macrophages is inhibited by lipopolysaccharide. *Inflammation* 29: 108-117.
- 25) Duan L, Gan H, Arm J and Remold HG (2001) Cytosolic phospholipase A₂ participates with TNF- α in the induction of apoptosis of human macrophages infected with *Mycobacterium tuberculosis* H37Ra. *J Immunol* 166: 7469-7476.
- 26) Tomioka H, Sano C, Sato K, Ogasawara K, Akaki T, Sano K, Cai SS and Shimizu T (2005) Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against *Mycobacterium avium* complex infection in mice and roles of cytosolic phospholipase A₂-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial host resistance. *J Immunol* 175: 6741-6749.
- 27) Vandal OH, Gelb MH, Ehrt S and Nathan CF (2006) Cytosolic phospholipase A₂ enzymes are not required by mouse bone marrow-derived macrophages for the control of *Mycobacterium tuberculosis* in vitro. *Infect Immun* 74: 1751-1756.
- 28) Harwig SS, Tan L, Qu X-D, Cho Y, Eisenhauer PB and Lehrer RI (1995) Bactericidal properties of murine intestinal phospholipase A₂. *J Clin Invest* 95: 603-610.
- 29) Vidal SM, Malo D, Vogan K, Skamene E and Gros P (1993) Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. *Cell* 73: 469-485.
- 30) Valko M, Morris H and Cronin MT (2005) Metals, toxicity and oxidative stress. *Curr Med Chem* 12: 1161-1208.
- 31) Karupiah G, Hunt NH, King NJ and Chaudhri G (2000) NADPH oxidase, Nramp1 and nitric oxide synthase 2 in the host antimicrobial response. *Rev Immunogenet* 2: 387-415.